Partnering to advance first-in-class mitochondrial oncology.
Mitophilix has built a first-in-class mitochondrial oncology platform centered on precision inhibition of oxidative phosphorylation (OXPHOS), a foundational metabolic dependency in aggressive and treatment-resistant cancers.
The platform is supported by, scalable chemistry, and extensive in vivo efficacy and safety data.
For partners, Mitophilix offers early access to a validated therapeutic axis with broad applicability across tumor types and combination strategies, grounded in transparency, scientific rigor, and aligned goals.
Partnership opportunities
We are actively seeking partners across the oncology ecosystem for:
Clinical development and commercialization partnerships for AGB374 in PDAC and other OXPHOS-dependent cancers
Global or regional licensing agreements with milestone and royalty structures
Combination therapy collaborations, including chemotherapy, targeted agents, immuno-oncology, and ROCK1/2 inhibitors
Co-development of biomarker and precision medicine strategies to optimize patient selection
Research partnerships to expand our mitochondrial oncology platform into additional indications
Our programs are designed to integrate seamlessly into existing development pipelines and clinical workflows, enabling rapid progression while reducing risk.
A De-Risked, High-Value Asset
Mitophilix has intentionally advanced its programs to a stage that enables efficient partnering. Our compounds demonstrate:
Validation
Clear mechanism-of-action confirmation through resistance profiling and multi-omics sequencing.
Efficacy
Robust activity in orthotopic, syngeneic, and genetically engineered mouse models.
Pharmacokinetics
Favorable PK with oral bioavailability that supports chronic dosing strategies.
Synergy
Demonstrated compatibility with standard-of-care regimens and targeted agents.
Safety
Early safety signals indicate a differentiated therapeutic window for patients.
This foundation allows partners to accelerate development timelines while preserving optionality across indications and combinations.
Our Approach
We view partnerships as long-term, value-creating relationships built on transparency, scientific rigor, and shared goals. Mitophilix works closely with partners to tailor collaboration structures that align incentives, leverage complementary strengths, and maximize the clinical and commercial impact of our therapies.
Let's Advance Cancer Treatment Together
If you are interested in exploring partnership opportunities with Mitophilix—whether in drug development, licensing, or strategic collaboration—we welcome the opportunity to connect.
Contact us at eradicatecancer@mitophilix.com.